Targretin

Bexarotene, sold under the brand Targretin, is an antineoplastic (anti-cancer) agent approved by the U.S. Food and Drug Administration (FDA) (December 1999) and the European Medicines Agency (EMA) (March 2001) for use as a treatment for cutaneous T cell lymphoma (CTCL).[1] It is a third-generation retinoid.[2] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Interactions 5 Mechanism 6 Physical properties 7 History 8 References Medical uses... [wikipedia]